0001193125-12-439172.txt : 20121029 0001193125-12-439172.hdr.sgml : 20121029 20121029124459 ACCESSION NUMBER: 0001193125-12-439172 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20121029 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20121029 DATE AS OF CHANGE: 20121029 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMEDISYS INC CENTRAL INDEX KEY: 0000896262 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] IRS NUMBER: 113131700 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24260 FILM NUMBER: 121166305 BUSINESS ADDRESS: STREET 1: 5959 S SHERWOOD FOREST BLVD CITY: BATON ROUGE STATE: LA ZIP: 70816 BUSINESS PHONE: 2252922031 MAIL ADDRESS: STREET 1: 5959 S SHERWOOD FOREST BLVD CITY: BATON ROUGE STATE: LA ZIP: 70816 FORMER COMPANY: FORMER CONFORMED NAME: ANALYTICAL NURSING MANAGEMENT CORP DATE OF NAME CHANGE: 19940819 FORMER COMPANY: FORMER CONFORMED NAME: M&N CAPITAL CORP DATE OF NAME CHANGE: 19930125 8-K 1 d429109d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 29, 2012

Commission File Number: 0-24260

 

 

 

LOGO

Amedisys, Inc.

(Exact Name of Registrant as specified in its Charter)

 

 

 

Delaware   11-3131700

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

5959 S. Sherwood Forest Blvd., Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Section 7—Regulation FD

 

Item 7.01. Regulation FD Disclosure.

On October 29, 2012, Amedisys issued a press release entitled “Amedisys Announces New $225 Million Unsecured Credit Facility and Amendment to Senior Notes,” a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless we specifically state that the information is to be considered “filed” under the Exchange Act or specifically incorporate it by reference in any filing under the Securities Act or the Exchange Act.

Section 9—Financial Statements and Exhibits

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

  99.1 Press Release dated October 29, 2012 titled “Amedisys Announces New $225 Million Unsecured Credit Facility and Amendment to Senior Notes” (furnished only)

 

2


Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

AMEDISYS, INC.
By:   /s/ Ronald A. LaBorde
 

Ronald A. LaBorde

President and Chief Financial Officer and Duly Authorized Officer

DATE: October 29, 2012

 

3


Exhibit Index

 

Exhibit No.

  

Description

99.1    Press Release dated October 29, 2012 titled “Amedisys Announces New $225 Million Unsecured Credit Facility and Amendment to Senior Notes” (furnished only)

 

 

4

EX-99.1 2 d429109dex991.htm PRESS RELEASE Press Release
LOGO    Exhibit 99.1

 

Contacts:

For Investors:

Amedisys, Inc.

Kevin B. LeBlanc

Director of Investor Relations

225.299.3391

kevin.leblanc@amedisys.com

  

 

For Media:

Amedisys, Inc.

Jacqueline Chen Valencia

Senior Vice President Marketing & Communications

225.299.3688

jacqueline.chen@amedisys.com

Amedisys Announces New $225 Million Unsecured Credit Facility and

Amendment to Senior Notes

Baton Rouge, Louisiana, (October 29, 2012) – Amedisys, Inc. (NASDAQ: AMED), one of America’s leading home health and hospice care companies, today announced that it entered into a new $225 million unsecured credit facility agreement and an amendment to its senior notes. The new credit facility is with a group of banks led by JPMorgan Chase Bank, N.A. and Bank of America Merrill Lynch, as joint book runners for the transaction. The new facility includes a $165 million five-year revolving credit facility and a $60 million five-year amortizing term loan. The senior notes were amended to allow a partial prepayment and to conform certain provisions to the new credit facility.

Proceeds from the new term loan and existing cash were used to pay off Amedisys’ existing term loan with a principal balance of $15 million and a portion of its existing senior notes with a principal balance of $60 million. Prepayment fees of $3.6 million were incurred associated with the senior notes, and will be reflected in the fourth quarter of 2012 financial results.

William F. Borne, chief executive officer of Amedisys, Inc. stated, “We are pleased to have reached a new credit agreement with our bank group and an amendment to our senior notes. The five-year revolving credit facility will support our capital needs, including acquisition opportunities, which we believe will become increasingly attractive over the term of the agreement. The strength of our balance sheet, coupled with this new credit facility and the amendment to our senior notes, will enable us to lower our on-going interest costs while improving the financial flexibility of our capital structure.”

Amedisys, Inc. is headquartered in Baton Rouge, La. Its common stock trades on the NASDAQ Global Select Market under the symbol AMED.

About Amedisys:

Amedisys, Inc. (NASDAQ: AMED) is a leading health care at home company delivering personalized home health and hospice care to more than 360,000 patients each year. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based recovery and rehabilitation after an operation or injury, care focused on empowering them to manage a chronic disease, palliative care for those with a terminal illness, or hospice care at the end of life. The Company’s state-of-the-art advanced chronic care management programs and leading-edge technology enables it to deliver quality care based upon the latest evidence-based best practices. Amedisys is a recognized innovator, being one of the first in the industry to equip its clinicians with point-of-care laptop technology and referring physicians with an internet portal that enables real-time coordination of patient care seamlessly. Amedisys also has the industry’s first-ever nationwide Care Transitions program, designed to reduce unnecessary hospital readmissions through patient and caregiver health coaching and care coordination, which starts in the hospital and continues throughout completion of the patient’s home health plan of care. For more information about the Company, please visit: http://www.amedisys.com.


This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect,” “anticipate” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Many of the factors that could cause or contribute to such differences are described in the Company’s periodic reports and registrations statements filed with the Securities and Exchange Commission, and include, but are not limited to the following: general economic and business conditions, changes in or failure to comply with existing regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical reimbursement levels, ability to complete acquisitions announced from time to time, and any financing related thereto, the ability to meet debt service requirements and to comply with covenants in debt agreements, adverse changes in federal and state laws relating to the health care industry, demographic changes, availability and terms of capital, ability to attract and retain qualified personnel, ongoing development and success of new start-ups, ability to successfully integrate newly acquired agencies, changes in estimates and judgments associated with critical accounting policies, business disruption due to natural disasters or acts of terrorism, and various other matters, many of which are beyond management’s control. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Our company website address is http://www.amedisys.com. We use our website as a channel of distribution for important company information. Important information, including press releases, analyst presentations and financial information regarding the Company is routinely posted on and accessible on the “Investor Relations” subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. We will also use our website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the Securities and Exchange Commission (“SEC”) disclosing the same information. In addition, we make available on the Investor Relations subpage of our website (under the link “SEC filings”) free of charge our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms 3, 4 and 5 and any amendments to those reports as soon as practicable after we electronically file such reports with the SEC. Further, copies of our Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct and the charters for the Audit, Compensation and Nominating and Governance Committees of our Board are also available on the Investor Relations subpage of our website (under the link “Corporate Governance”).

###

GRAPHIC 3 g429109g70a99.jpg GRAPHIC begin 644 g429109g70a99.jpg M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\< M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3H.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1 M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`%,`Q0,!$0`"$0$#$0'_V@`, M`P$``A$#$0`_`/?B<4`&:`#-`!F@`S0`9H`,T`&:`#-`!F@`S0`9H`,T`&:` M#-`!F@`R:`#-`$5QRDOBT,_:QZ:DB:EXFNN8="M[13T-W=Y/_?*`_P`Z.6"Z MCO-]"98_%+Z3'["UE?]?,'\J5Z?9_U\A^_P"0NWQ-'S]HTJ?V\B2+]=[4 MO<\P]_R(W\1RZ:P&N:>]E$3C[4C>;`/]YAROXC'O5`>K'N37KTL/",=5<\NI7FY:'9>!O&/C/QA92:;: MSV44UM@S:A,NY]IZ80<$\'FN>M2ITG=_<;TJM2HK([>T\!:;YRW6M3W&MW@Y M\R]?<@/^S&/E'Y5S.M+:.AT*DMY:G41Q1PQK'$BQQKP%48`_"L=S6UMAU`!0 M`4`-=%D1D=0R,,%2,@CTHV`XJUURR\':K?Z'>-Y5A'LGL>>B/G1U4I+?J<_.J;<6=P:YCH$H`CGGBMK>2>9PD4:EG9N@`ZFFE=V0F['"V7Q M?\,ZAJ-K8VPO#-<2B)2T0"@DX!)STKH>%J15V8+$0;LCOJYCH"@`H`*`"@`H M`*`"@`H`X;QOX]OO"!++X=FN+7(7[6TH6,L1G``R:Z*-%5.IA5JNGT.=\,_% M;4/$?B55FAM=-T>V@>6[9VW'`&!\QQCDCBMJF&4(Z:LRIXASEV1)??$36O%N MI/HW@6S(4<2:A,N`@]0.P^O/M25"--RU2VN6< M9E,H,9#'KCKD5K'&1ZHREA9=&>D>`/`\?@K2I8GG%Q>W+!II%&%XZ*/8);**Q4L]O:@R8[;F;'_`*": M]#"R48NYQ8A>=HE`'F?Q)U6ZUG4K/P+HS_Z5>D-=N/\`EG'UP?YG MV`]:[*$5%.K+H$U9GM+4K7NK:=IL,DU[?001QC+&20#%-1D]$B7)+=@NJV#:6NI MB\B%BR"03LV$VGODT:-*U&"[,.-XC;)6G*$H?$@C M.,MF1:KXL\/Z'.L&I:M;6TQ_Y9L_S#Z@=*<:0C' M+GZ*.:(4Y3^%"E.,-V>1_%/Q_I7B'0+?3-,-P6\\2.986C&T`XQGKR:[\-0E M"7-(X\15C*-D9'@SP/=>(O#HRXM;.ZNLW%RW:.,<`>I+,?\`OFKK5E"7F9TJ M3E$]GTE_"_A:*RT.PNK6!YSMBC$@+RMZG'4^YKSY>TJ7DSNCR0M%&AJGB+1M M$(&IZI;6C'HLD@#'\.M3&$I;(MSC'=D>E^*=!UJ7RM-U:UN9?[B2#=^76B5. M<=T*,XRV9I6PN;&ZBN83T>)PP_2H M<7%V9:::NBST]J0SG/#L,&H7>J:[Q)'?3!((+;PQX?NM4N<'REQ&G]]S]U?SK2G!SDHHBI-0C=GE7P[\ M4^&=,>_U[7]9C_MS4)"7!C8F-,].!W_D!797ISE:$%HCDHSC&\I/5GFOBRXL M[OQ9JMSI\HEM)KAI(W`(R"<]_K7;234$F;-)5+([SQQI]WJ/@8:Q+=O9Z/:^7#IEB%QYJ_=$C^Y'('85RT9 M*-3EMKU9T54W"_3H97PJ74`VHQ:.RIJ5Z%@21AE;>,3[SO@9S^.16]*5X)VL8U8VFT>H^*O% M]QX%\&:/X:TZ3;JIM$\V7J85QV]R![GP]I MFD7^O:TRZIK5P6CMK0J9I#QU(YQD]SV%:UE-R4(Z(SI.*BY2U93TB;5/ASIU MSJ]Q#]EU+4XS#9V[CE%SEI&7L!P`#524:[45LB8MT5S/=FY\)/#C>)-;N_$N MLEKL0-MC,QW;Y3R2<^@_G[5GB9^SBH1+P\.=NK!1I(Y;X5Z>[:OJ6MK%YG]DV2%2'B:0Y;:PR,GOZ?A7H4)\\$SBK1Y)M'M^A:5I.L?"32 M$UF+S+*"U$SKO*CY0>3@UYLY2C6?*=\(QE25SP=8K_3M!FU&V,D%CJ$K6RD' M!=5^8C/IT_(UZ=XRERO='GZQC=;,[[X5^(?"\>E3>'-:M8(Y;F0XFE0%901C M:3V([5RXF%3FYXG1AYPMRR/1OAWX0?PCI=]!,JB6>Z9P5?<#&.$_'%K[1 MIG51I\B:+^OW4VH7*^'=/D*SW"[KN9?^7>#N?]YN@_$]JF"4??94G?W4;MM; M0V=K%;6\8CAA0(B#H`!@"LV[NY:22L2NRHI9B%51DDG``I#/&;^^7XH_$>VT MFWV:[XQ^KTN9[LX6_;5.7HCUU=.L54*ME;@#@`1+Q M^E<7-+N=G*NQ\X_%JUBM?B'>K"BHK1QMM48`.T?X5ZV%=Z:N>9B%:H['IOPQ M\0P0?"N2XFD'_$J\T.">@'S#^=<6(@W6MW.NA.U*_8\A\):4_C'QW;P7`+)/ M,T]Q_N@[F_/I^-=]67LJ>AQ4X^TJ:GH7QTU9(K?2M#A(5>9W4<``?*H_G^5< MN#CJY,Z<7*R44:_PKTR'PU\/;G7[A`)KE&N&8]?+4':/T)_&L\3)SJ M2GS'B=GJ2OXGAU.]A>Y#70GDC7[TGS9P*]%QM#E1P*7OW98\8ZC?:KXLU&[U M"W:VN6DP86.3&```OX#%*C%1@DAU6Y3;9[_X>U/P]X<^'NFW\MQ;1P1VJDN, M;V;'('&_#F\ZG+N-Y<;"$M`S'+$]"V/N@5QUH MVJ.<]CKHRO!1B>37\T8\5R-9V_F10W(2&'J7"MA0?4G'/UKNC\&IQ/X]#L/B MCJ^KR6^DZ7K$JF\VM>31(,+"7.$C'KM`_6L,-&*;E$WQ$I649%?P+X]C\(Z0 MUK%IWF2W5XOGW$A^18\`8`]<9-.M1]I*]]A4:OLU:QN?$OX9VFFV,_B/1)%2 MU!#S6Y/`#'[R'TYZ5GA\0V^21=>@DN>(OP(>\_M;544M]A\E2X_A$F>/QQFC M&VLNX82]WV,SXW1A/&\+CJUHA/YM5X/^&3BOC.G62[U;P9X<\#Z6Q6YN[2.6 M^E'2W@Z\^[>G^-8:1G*I+IL;7&1/-AD`P2N2.1V/%>A1J M^UC?EDD/90,>YZ"O.J0CSM M]#OA)J"74Z[1='CT>T93(T]U,WF7%P_WI7]3Z#L!V%83ES,VC'E1I5!1A>(? M"MOXD=5O;^_CM=FQK:"?RXWY)RV!D_GVK2%1PV1G.FI[LS-*^&VAZ#K$>I:1 M)>6W2X^20`Y`/%-XF;U=A?5XK1&WX>\#>'_"]PUSI5D8KADV&1 MI&9MOIR?:LYUISTDRX4HPV)KSP?H&HZL^IW^FQ7=VP"[IOG"@=``>!256<5R MIC=.+=VB]?:3:WVBSZ2R"*UFA,)6(;=JD8X]*E2:ES%.*:Y3D_"WPJT'PS>B M^W2WUVAS&\^,1^X4<9]ZWJ8F,'_O12Q,J:MT"IAXS=QGAWX2>'=!N8[J7S=0N(SN0W!&Q#ZA1QGZT5,3. M:ML$,/&&IKZYX`\-^(M1%_J6G^9&;WP_!HQL?*MX"6C>-L.&/5MWCAY*E2YI'!73J5.6)Z[X1\*6OA32A;QN9[N0`W%RWWI"!@?0# MH!7#5JNH[]#MITU!6,S5_AII.HZX=;L[J[TS4BV\S6LF,MZX-7&O*,>5ZHB5 M&+?,M&+"RW=ZX-M:8Z;@H`9O1!^-;*JXQUT1DZ:< MM-6>D:)H5MHENZQLTUS,=T]S)]^5O4^@]`.!7).;DSIC!1-2H+"@!30`E`!0 M`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`<)\5_^$A_X19!H`N"3+_I'V?/F;,= ML_D3"=62M:QVGAOPO8>&;61+;=-=3G?<74IS),W7KOB[_`%ZS:)HC?\LP M<75P/<_\LU/IU^E:^Y3VU?X&?O3WT1T^GZ=9Z591V=C;I;V\8^5$&!]?<^]8 MRDY.[-4E%619I#"@`H`4T`)0`4`%`!0`4`%`!0`4`%`!0`@(89!!'M0`M`!0 M`4`%`!0!D:UXHT7P^F=3U&*%S]V+.Z1OHHY-7&G*>R(E4C'=F(-:\3>(QMT3 M3?[)LF_Y?M17]X1ZI%_\56G)"'Q.[\B.:<_A5C2T?PA8:7=?;[AY=1U0_>O+ ML[G'^Z.B#V%3*JY*RT14::6KU9T%9&@4`%`!0`4`*:`$H`*`"@`H`*`"@`H` M*`"@`H`P-7TO5DF:_P##U['!ZU MI1V:[X-U"/;P9K+$\9]QBM?8QE\,C/VLH_%$8/C%X34E9GO8)!U22V8$4_JM M3H'UF"W)%^*NE7"@Z=I&LWQ/3R;,X/XFE]6DMVD/VZZ)CAXI\9:E\NE^#&M5 M/_+74;@(!_P$ GRAPHIC 4 g429109g97d77.jpg GRAPHIC begin 644 g429109g97d77.jpg M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\< M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3H.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1 M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`#L`D`,!$0`"$0$#$0'_V@`, M`P$``A$#$0`_`/?SQ0`F:`#-`!F@`S0`9H`,T`&:`#-`!F@`S0`F[`))`%`# M(KB*=2T,J2*#C*,",_A0[K<+I[&7>>)]*LKDVIN?M%V/^7>V0S2?BJYQ^.*M M4Y/4ER2T&+J>M78_T71/LZGH][.$/_?*;C^>*.5+=BO)[(<(_$S')O-+C_V? MLLC_`*^8/Y47AV8>_P"0X2:_;C=)'97H'\,6Z%C]-Q8?J*7NO8%S+PF[;F5;^+=`N]2@TZTU M6WN;N?<4CA??P!DY(X'XU;IS2YFB54BW9,X;XJ>)DO=(F\/Z'=X\L=SB?A/H5_JFN30R"\AT;RR;H1R/$LC? MPJ2,9^@KHQ,XQC=;F&'C)O78]_L--L=*MA;V%I%;0C^&)`H_'UKS')RW/022 MV+5(84`%`&#J,8MO%FB747RO\>$M02[\$Z1>R2*JM:1[F8X`(&#^HKS:D;3:. M^G*\$V6X?$&D7.HII]OJ5M-=LA<11R!CM'4\5+A)*[12DF[7([/Q-HFH:I+I MEGJ=O/>Q`EHHWR0!UIN$DN9K0%.+=DQJ>*]!DU@:1'JML^H$D"%7R`9'`)^@ZG\*E1E+9#(]' MUZ&672]0ANDA.)"C?<^H/2JE"4?B0*2EL7'C=)@D M\D_*/Q-=]>:BU%JYQT87N[V/;/"T?A+P_IMS::+>6GEV@4W<_F`G)Z%WZ5YU M1U)M.2.V')'9EVU\:>&;NYCM;?6;1I9#A%W;0Y]B>#^%3[*HE>Q:J0O9,MS> M)-$@N(K>35;03RR")(Q*"S,>@P*%";5[!SQ3M<2X\3:)::O%I,^IVZ:A*0$@ M+_,2>@]OQHY)-,[7P^0I]"1P*?LI]A>TBN MIMP3Q7,"3P2++$XW(Z'(8>H-19K1FBUV,<_\3+Q?%M_U&E1L6/8S2#`'X)G_ M`+Z%5M'U(WEZ&Z>E07L>=?$*_OM:N8O!>A*)+NY3S;T[]@CA'\);MN_SUKJH M*,?WD]C"JW)\D=SD?BC:ZTGA/3$O=&LK"RLIA'$;>Y,A&5(`P5'''6ML,X\[ M:=VSGKJ7(DT=+\/KNQO/@\PU.*.>ULA,)(Y0"N%)8XJ,;S=MBEX3;3K?QSJ.N M0Q>7I6D+-=QQ[NH&5C7)ZDDBJJBUC0O5JN;^1M6_=T^5&)J:Z+8_!C3[<);W&J7$X8O@%H2WS MD9[?*%&/>M(&KX_".R:P7S9)K@WMY!&5@JC%>I48)_ M&CVB]O[PO9OV7NFUX+\0:;XU&C>&-?LXQ-8.)+21$&V944_(P/3(_/%9UJ,KM='2"WDTRW823KA#/=ORD>[NV!^%<]*I[.'O=?R-ZM/VDM. MAQGA7Q0/#4&H>%M>T\C3KUBEQE,2P,1MW8/4#@_J*Z:M/GM.#V.>G/DO":/= MO,BT'2+#1])19KKR5CM8^@V@8,C8Z*.I]3P.37F_$W*1Z"T5D:>E:MZI?:AJ,&HOJ&&>?T%:U:L9I)*UC*G3<6VR7QU MX5U/QA9QZ7%=VMI8!UE=V1GD+#/`'`QS10JJD^;J%6FYJQS5C\,?$&E^'M3\ M/VVMVC:?J#*S2-$PD3&,X&<'(`!YK5XB#DIM:HS5"2BXIF_HG@`Z%X'OM`M= M1`N+TMYEWY6"-P`.%SV7@%_"^J:7IMX[W-]& MP-Q*H&&V[1P.P_K1.LZDE)K8(4E"+2.0T'X)K!IMX-9OD>[FB,<(AR4A/9CG M&XUO/%MME5KTJ MG34JG1G#9DVJ?!2VN]:2\L]8EMH<*7#)OD+CJ^[/4GGZTHXMQC9H)89-W3-? MQ/\`#&WUW2K&RAU*6W,$[33SRCS9)R0`68DCGCCL*BGB'!MV+G1YE8QO%'PC MEO[;1K#0[J"VL;)&63SLEF9B"7X')./:KIXGE;*KGQ+J< MT#7DCN\5O:J1%$6ZGGD\&E4Q'-!0B%.CRRYI'(^(-/U+7?CBYT15:6R\HR3. M,I"0O5O4C/`[D5O"488?WC.<7*MH=SK'@>Y;0=.LM"U!;:YL;L7ADG7=]HE' M)9R.5/1),Y;Q-X6U'Q5XMM&U$6#7<$:J]K9%F!&<[I9"!M7 MT')(X'K6M.K&G!I7U,YTW.2;/3M*TE=.5Y99?M%[-CSIR,9QT51_"H[#^O-< M,\_C2=KZ#5[:F;_`&9K5K;D17)D95BB M##`;8`2V.>N2.?04[Q)LT2RV^N2S3Q;AY'V9H@VX`2,0H#8['[Q_QI>Z@]X2 MXTO4'\Y8I)443[X_WHP%6/"!?3+=:$T@<7T+NL6MQ"`I8?W@ M3RN>HI1M*6PK/N2S6VJ-+<1 M++FVPJQ%B"6SM#$_0!C[DT:#LR&>'66MI!$\BSF2:9LR3N>I)ZLQ]JP;E49JE&"(!<:QX@XM$DTG3CUN)5Q<2C_80_<'NW/M3 MM&.^K#66VB-C3=,M-)M?L]G$$4G ME`"8H&%`@I6`*8!C%`!2L`4P,74M;;FW)V:3:7^K/V^RVS;/^^VPH_.G[&2^+0GVD M7MJ+_P`5=JW!6UT*W/?/VBXQ^B+^M'[N/F-<[\B]IWAC3]/N!=L)+R_[W=V_ MF2?@3PH]E`J95)/3H-02U-FH+"@`H`!UH`=0`4`&*`#%`!0`4`%`!0`8H`S[ MK0M(OFW7>E6=PWK+;JQ_452G);,EPB]T);Z!HUF